Clinical Trials Browser

Pleural Effusion, Malignant × Bevacizumab × Clear all

NCT05330065 2022-04-15

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Phase 1/2 Unknown

Pleural Effusion, Malignant

NCT02054052 2019-03-29

Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Pericardial Effusion, Pleural Effusion, Malignant

NCT02942043 2018-11-07

Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer

Phase 2 Unknown

Pleural Effusion, Malignant

NCT02250118 2017-11-06

BEVAP

Phase 1 Terminated

Breast Neoplasms, Neoplasms, Pleural Effusion, Malignant

NCT00533585 2016-02-10

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

NCT01661790 2015-03-25

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Phase 3 Completed

72 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT02054078 2014-02-04

Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion

Phase 2 Unknown

Pleural Effusion, Malignant